实用医学杂志 ›› 2022, Vol. 38 ›› Issue (4): 452-458.doi: 10.3969/j.issn.1006⁃5725.2022.04.011

• 临床研究 • 上一篇    下一篇

肺大细胞神经内分泌癌临床特征及预后分析

陈云荣1 刘达2   

  1. 1湖南省人民医院(湖南师范大学附属第一医院)呼吸与危重症医学科(长沙410016);2南华大学附属长沙中心医院呼吸与危重症医学科(长沙410111)

  • 出版日期:2022-02-25 发布日期:2022-02-25
  • 通讯作者: 刘达 E⁃mail:306830911@qq.com
  • 基金资助:
    湖南省卫健委科研项目(编号:202103021003);湖南省自然科学基金(编号:2021JJ40622,2021JJ30398)


Clinical characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma

CHENYunrong*,LIU Da.   

  1. Department of Pulmonary and Critical Care Medicine,Changsha Central Hospital Affiliated toUniversity of South China,Changsha 410016,China

  • Online:2022-02-25 Published:2022-02-25
  • Contact: LIU Da E⁃mail:306830911@qq.com

摘要:

目的 评估肺大细胞神经内分泌癌(pLCNEC)临床特征、肿瘤标志物、治疗方法等对预后的影响。方法 通过电子病历回顾分析 149 例 pLCNEC 患者病历资料,通过 Kaplan⁃Meier 曲线及 Cox 回归分析患者临床特征、血清肿瘤标志物(NSE、CA125、CA153、CYFRA21⁃1)、病理类型(复合型、单纯型)以及治疗方法(手术、化疗、免疫治疗)等对预后的影响。结果 149例患者中位年龄63岁,其中男 136(91.28%)例;单纯 pLCNEC 100 例,复合型 pLCNEC 49 例;中位生存期为 18(10,32)月。血清 NSE、CA125、CA153、CYFRA21⁃1 水平增高的患者总生存期(OS)明显缩短(HR 分别为 2.959、4.249、5.198、1.84,均 P < 0.05)。预后差的相关因素还包括:肿瘤 TNM 分期(与Ⅰ期患者比较,Ⅲ期、Ⅳ期患者的 HR 分别为 4.074、9.470,P < 0.05),淋巴结转移或远处转移(HR = 1.815、4.083,P < 0.05)。其中 CA125、CA153、淋巴结转移、远处转移是预后的独立危险因素。接受手术治疗的Ⅰ⁃Ⅲ期患者 OS 明显延长(HR = 0.357,P < 0.05)。复合型pLCNEC 与单纯 pLCNEC 的 OS 无差别,但合并小细胞肺癌的复合型 pLCNEC 预后更差(HR = 2.051,P =0.024)。CEA、CA125、CA153 阴性的患者手术治疗的 HR 分别为 0.256、0.479、0.388(均 P < 0.05),而 CEA、CA125、CA153 阳性患者手术治疗的 HR 分别为 0.548、0.628、0.746(均 P > 0.05)。结论 CA125、CA153、淋巴结转移、远处转移是 pLCNEC 预后差的独立危险因素;合并小细胞肺癌的复合型 pLCNEC 预后更差;手术治疗显著改善Ⅰ~Ⅲ期pLCNEC 患者预后。

关键词:

肺大细胞神经内分泌癌, 肿瘤标志物, 临床特征, 治疗, 预后

Abstract:

Objective To evaluate the effect of different clinical features,tumor markers,TNM stage andtreatment strategies on pulmonary large cell neuroendocrine carcinoma(pLCNEC). Methods A cohort of 149patients with pLCNEC were retrospectively enrolled. All data were collectedfrom the electronic medical records.The effect of clinical features and factors,including serum tumor markers(NSE,CA125,CA153,CYFRA21⁃1),TNM stage,pathological types(pure or combined),and treatment strategies on prognosis were analyzed by KaplanMeier curve and Cox model. Results Of the 149 patients,the median age was 63 years and 136(91.28%)weremales;100 were pure pLCNEC and 49 were combined pLCNEC. The median survival time was 18(10 ~ 32)months. The overall survival(OS)of patients with increased serum NSE,CA125,CA153 and CYFRA21⁃1 levelswas significantly shorter(HR = 2.959,4.249,5.198,1.84,P < 0.05). The poor prognosis also associated withthese factors including tumor TNM stage(compared with stage I patients,the HR of stageⅢ and Ⅳ patients were4.074 and 9.470,respectively,P < 0.05),N and M(HR = 1.815,4.083,P < 0.05). CA125,CA153,N and Mwere independent risk factors of poor prognosis. The stage Ⅰ ⁃ Ⅲ patients treated with surgery had significantlylonger OS than patients treated without surgery(HR = 0.357,P < 0.05). The OS of combined pLCNEC patientswas similar to pure pLCNEC patients,but the OS of pLCNEC patients combined with small cell lung cancer wassignificantly shorter(HR = 2.051,P = 0.024). Surgy⁃treatment was very efficient in patients with negative CEA,CA125 or CA153(HR = 0.256,0.479,0.388,all P < 0.05),but surgy⁃treatment became less efficient in patientswith positive CEA,CA125 or CA153(HR = 0.548,0.628,0.746,all P > 0.05). Conclusion CA125,CA153,N and M are independent risk factors of poor prognosis of pLCNEC. The prognosis of pLCNEC combined with smallcell lung cancer is worse. Surgical treatment significantly improved the prognosis of stage Ⅰ⁃Ⅲ patients.

Key words:

pulmonary large cell neuroendocrine carcinoma, tumor markers, clinical characteristics, therapeutics, prognosis